Literature DB >> 1955680

Detection of anticardiolipin antibody in patients with cocaine abuse.

G A Fritsma1, J B Leikin, A J Maturen, C J Froelich, D O Hryhorczuk.   

Abstract

Anticardiolipin antibody, an immunoglobulin that binds negatively charged phospholipids, is considered to be an in vitro inhibitor of clot-based coagulation procedures. We adapted an enzyme immunoassay using stationary cardiolipin antigen to compare anticardiolipin antibody activity in the plasma of 44 cocaine abusers with its activity in the serum of 72 blood donors and a sample of 203 random specimens from healthy volunteers. Activity of 20 of the 44 abusers and 43 of 203 random specimens exceeded the donor control reference range. Patients using intravenous cocaine were more likely to have elevated activity than those who inhaled (P less than 0.05). Of 7 patients who had seizures or thromboembolic disorders, 5 were anticardiolipin antibody positive. Enzyme immunoassay may have predictive value for ischemic disease in cocaine abusers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955680     DOI: 10.1016/0736-4679(91)90586-5

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  3 in total

1.  A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine.

Authors:  Rachel L Gross; Jason Brucker; Asena Bahce-Altuntas; Maria A Abadi; Jules Lipoff; David Kotlyar; Peter Barland; Chaim Putterman
Journal:  Clin Rheumatol       Date:  2011-06-25       Impact factor: 2.980

2.  Levamisole-induced occlusive necrotising vasculitis in cocaine abusers: an unusual cause of skin necrosis and neutropenia.

Authors:  Cassius D Belfonte; Victoria K Shanmugam; Nicole Kieffer; Shodeinde Coker; Suelyn Boucree; Gail Kerr
Journal:  Int Wound J       Date:  2012-06-21       Impact factor: 3.315

3.  Levamisole-contaminated cocaine: an emergent cause of vasculitis and skin necrosis.

Authors:  Osama Souied; Hassan Baydoun; Zahraa Ghandour; Neville Mobarakai
Journal:  Case Rep Med       Date:  2014-03-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.